Immunofluorescence of phenobarbital inducible cytochrome P-450 in the hepatic lobule of normal and phenobarbital-treated rats
β Scribed by Kunihiko Ohnishi; Akihiko Mishima; Kunio Okuda
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 973 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
The localization of the form of cytochrome P-450 that is induced by phenobarbital was studied by direct immunofluorescence in the hepatocytes of rats pretreated with phenobarbital in comparison with saline-treated rats. Specific fluorescence was seen in the hepatocyte cytoplasm in saline-and phenobarbital-treated rats; a more concentrated halo of fluorescence was detected surrounding the nuclei in the centrilobular zones after phenobarbital treatment. In the saline-treated rats, fluorescence was barely discernible but slightly more intense in the centrilobular than perilobular zones. In phenobarbital-treated rats, fluorescence was much more intense, with a similar but much greater difference between the centrilobular and perilobular zones. The tissue distribution and induction site of this component of the cytochrome P-450-dependent microsomal system may be relevant to the site of drug toxicity and the development of chemical carcinogenesis.
π SIMILAR VOLUMES
The abilities of structural congeners of phenobarbital to induce immunoreactive hepatic cytochrome P450 2B (CYP2B) protein and associated catalytic activity (benzyloxyresorufin 0-dealkylation) in the male B6C3F1 mouse were examined. Interspecies differences in inducing ability were examined through
The influence of both single and concurrent administration of phenobarbital and clofibrate on hepatomegaly, cytochrome P450-dependent mixed function oxidase activities, and peroxisome proliferation in male rat liver have been studied. Both xenobiotics separately increase the liver: body weight ratio
the Association pour la Recherche sur le Cancer, and the European Economic Communities (BIOMED; contract BMH4-CT96-0254). Karine Mahe Β΄o is a recipient of a fellowship from the Ministe `re de la Recherche et de l'Enseignement Supe Β΄rieur, and Sophie Langoue Β¨t is a recipient of a fellowship from th